# The COVID-RASi Trial (COVID-19)

> **NCT04591210** · PHASE3 · COMPLETED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 372 (actual)

## Conditions studied

- COVID-19
- Cardiovascular Diseases

## Interventions

- **DRUG:** Angiotensin converting enzyme inhibitor
- **DRUG:** Angiotensin II Receptor Blockers

## Key facts

- **NCT ID:** NCT04591210
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-27
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591210, "The COVID-RASi Trial (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04591210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*